This six-part orientation is strongly recommended for all clinical research personnel who are new to UNC or new to research. The series will introduce research personnel to the UNC offices involved in clinical trials, discuss the federal and local regulations governing conduct of research, and provide an overview of best practices utilized in the implementation of clinical research. It is recommended that registrants complete both the CITI Good Clinical Practice (GCP) and CITI Human Subjects Protection (IRB/Ethics) modules prior to attending the orientation.

Each session of the orientation will be held on Wednesday afternoons,1:30 to 4:30pm. Research personnel are encouraged to attend all 6 modules, but may choose to attend only those of particular interest or relevance. The topics to be covered this week include:

• UNC Institutional Review Board Processes (IRB Analysts / Staff) - 1:30 pm - 3:30 pm
• Conflict of Interest (Joy Bryde) - 3:30 pm - 4:00 pm
• Post-Session Q&A Discussion 4:00 pm - 4:30 pm

Register

The REDCap Open Training Session will review using surveys and provide ample time to answer any questions REDCap users might have.

Our current REDCap trainings are offered as webinar-only.

Register

About REDCap

REDCap is a secure web application that can be used to build and manage case report forms, surveys and other data capture mechanisms for clinical research. NC TraCS provides training classes to assist you in getting started with building REDCap data collection forms for your research projects.

Current REDCap training offerings include:

1. Forms (beginner)
2. Forms: Hands On (beginner)
3. Functions (advanced)
4. Open Session (Surveys and general questions)
5. Clinical Data Management (3-day)

For more information, please visit our REDCap webpage.

Join this month's journal club to discuss the use of real world data to evaluate the effectiveness of the BNT162b2 mRNA vaccine as described in this recent paper: BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Background

As mass vaccination campaigns against coronavirus disease 2019 (COVID-19) commence worldwide, vaccine effectiveness needs to be assessed for a range of outcomes across diverse populations in a noncontrolled setting. In this study, data from Israel's largest health care organization were used to evaluate the effectiveness of the BNT162b2 mRNA vaccine.

Discussion Leaders

Michele Jonsson-Funk, PhD and Sara Dejene

Register